Greenleaf Trust Trims Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Greenleaf Trust trimmed its holdings in Bristol-Myers Squibb (NYSE:BMY) by 26.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 53,891 shares of the biopharmaceutical company’s stock after selling 19,419 shares during the quarter. Greenleaf Trust’s holdings in Bristol-Myers Squibb were worth $2,765,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. True Wealth Design LLC purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth approximately $26,000. Coppell Advisory Solutions Corp. purchased a new position in Bristol-Myers Squibb during the 4th quarter worth $31,000. Coppell Advisory Solutions LLC purchased a new position in Bristol-Myers Squibb during the 2nd quarter worth $28,000. Live Oak Investment Partners purchased a new position in Bristol-Myers Squibb during the 4th quarter worth $33,000. Finally, OFI Invest Asset Management purchased a new position in Bristol-Myers Squibb during the 3rd quarter worth $25,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Stock Performance

Shares of BMY opened at $48.93 on Friday. The stock has a 50-day moving average of $51.23 and a two-hundred day moving average of $51.51. The stock has a market cap of $99.17 billion, a P/E ratio of 12.68, a P/E/G ratio of 1.46 and a beta of 0.39. Bristol-Myers Squibb has a one year low of $47.58 and a one year high of $70.93. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.31 and a current ratio of 1.43.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 EPS for the quarter, topping analysts’ consensus estimates of $1.55 by $0.15. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The firm had revenue of $11.48 billion for the quarter, compared to the consensus estimate of $11.19 billion. During the same quarter in the prior year, the business earned $1.82 earnings per share. The company’s revenue was up .6% compared to the same quarter last year. As a group, research analysts predict that Bristol-Myers Squibb will post 6.63 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be given a $0.60 dividend. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $2.40 annualized dividend and a yield of 4.90%. Bristol-Myers Squibb’s dividend payout ratio is presently 62.18%.

Analysts Set New Price Targets

Several research firms have commented on BMY. Societe Generale downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Wells Fargo & Company increased their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research report on Thursday. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Redburn Atlantic cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their target price for the company from $77.00 to $54.00 in a research report on Tuesday, February 6th. Finally, Bank of America cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their target price for the company from $68.00 to $60.00 in a research report on Wednesday, January 3rd. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $61.18.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.